elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Lab
API & MCP
Pricing
Log in
Sign up
Home
/
Subjects
/
Pharmacophore
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Pharmacophore
RIS
0.002
(Research Intensity Score)
Papers
212
Top papers
Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design
2021 · 689 citations
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
2021 · 802 citations
Current Research on Zinc Oxide Nanoparticles: Synthesis, Characterization, and Biomedical Applications
2022 · 294 citations
FDA-Approved Trifluoromethyl Group-Containing Drugs: A Review of 20 Years
2022 · 194 citations
Photoinduced Copper-Catalyzed Late-Stage Azidoarylation of Alkenes via Arylthianthrenium Salts
2023 · 137 citations
Newest papers
High-throughput screening and structure-guided design of small molecules enable modulation of SAL-PAP stress signaling
2026 · 2 citations
Isothiocyanate-mediated cyclization of phage-displayed peptides enables discovery of macrocyclic binders
2026 · 2 citations
Receptor-targeted technetium-99m radiopharmaceuticals: increasing access to molecular imaging in healthcare
2026 · 2 citations
Pharmacophore‐Guided Interfacial Ligands Co‐Optimize Charge Extraction and Heat Dissipation in Semitransparent Perovskite Solar Cells
2026 · 1 citations
Nuclear‐Targeted Boron‐Lapatinib Hybrid for Enhanced Boron Neutron Capture Therapy in Advanced Thyroid Carcinoma
2026 · 1 citations
A sample from the 100 top papers behind Pharmacophore.
Create a free account to browse them all →
Pharmacophore's history
Research intensity over time
Explore Pharmacophore's full history
Hover any year for its value and switch resolutions with a free account. Personal adds monthly detail and the historical-intensity (HRI) line.
Create a free account
Already have an account?
Log in
to explore the data.
Close ✕
Pharmacophore's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link